CEPI Commits Up to $8.5 Million for Hilleman Labs to Make Clinical-Trial Doses of Bundibugyo Ebola Vaccine
The Facts
- CEPI is providing up to $8.5 million to Hilleman Laboratories — a Singapore-based joint venture between Merck (MSD) and the charity Wellcome — to advance development and manufacture the first clinical-trial doses of an experimental Bundibugyo Ebola vaccine, announced on July 30, 2026.
- The candidate is a single-dose vaccine built on the recombinant vesicular stomatitis virus (rVSV) platform, the same backbone as Ervebo, the only licensed Ebola vaccine, which targets the Zaire strain; WHO experts have called the rVSV Bundibugyo candidate the "most promising".
- There is currently no approved vaccine or specific licensed treatment for the Bundibugyo strain of Ebola.
- Hilleman is to finalise the manufacturing process and produce clinical-trial supplies, with doses expected to be manufactured by the end of the year and human studies to follow soon afterwards, according to CEPI and Merck executives.
- The outbreak in the Democratic Republic of Congo was declared in mid-May and has affected five provinces in the east of the country; reported tolls rose from 3,262 cases and 1,437 deaths as of late July to 3,532 confirmed cases and 1,556 deaths, a case fatality rate of 44.1%, making it the second-largest Ebola outbreak on record by reported infections.
- CEPI Chief Executive Richard Hatchett said in a statement that "with Bundibugyo virus cases rising at worrying speed, the epidemic is fast becoming a humanitarian crisis" and that the candidate "could become an important tool for Bundibugyo outbreak control and response."
- A United Nations official warned that the epidemic is spreading faster than responders can contain it, and Congolese health authorities have said the peak of the outbreak has not yet been reached.
- The Hilleman-CEPI project is one of several parallel efforts: a separate experimental vaccine developed by University of Oxford researchers using ChAdOx1 technology has begun human testing, with a first volunteer dosed on July 24, a launch welcomed by WHO Director-General Tedros Adhanom Ghebreyesus; Russia's Gamaleya centre has separately reported that prototype vaccines produced immune responses in laboratory tests using simplified surrogate versions of the virus rather than the circulating strain.
Context
Why can't the existing Ebola vaccine simply be used?
Ervebo, the only licensed Ebola vaccine, is approved against the Zaire strain, not Bundibugyo news.bloomberglaw.c…,RFI. Africa CDC has said it plans to present evidence to the World Health Organization's vaccine advisers as it seeks to test whether Ervebo can provide at least partial protection against Bundibugyo and help protect frontline health workers, according to Bloomberg reporting news.bloomberglaw.c…,Bloomberg Business.
What happens next before the vaccine could be used in the outbreak?
Hilleman is to finalise the manufacturing process and produce doses for clinical trials, with manufacturing expected by the end of the year and human studies to follow RTTNews,Moneyweb. Trials must first confirm safety and efficacy before any deployment Africanews. Separately, the WHO has framed the Oxford trial as an important step to evaluate the safety and immune responses induced by that candidate RFI.
How large is the outbreak and who is affected?
Health Ministry data cited on July 31 put confirmed cases at 3,532 with 1,556 deaths — a 44.1% case fatality rate — surpassing the roughly 3,470 cases of the country's 2018–2020 outbreak, with some 807 patients in isolation or hospital Anadolu Ajansı. Five provinces in eastern DRC have recorded cases, and authorities say the peak has not yet been reached RFI,Africanews. Health workers on the front line are among those the vaccine efforts aim to protect news.bloomberglaw.c….
Where Left and Right agree, and where they split
- Where Left and Right agree
- With no licensed vaccine or treatment for Bundibugyo and a 44.1% fatality rate, the rVSV candidate is the credible bet — and reaching first doses only now carries a real human cost.
- Where Left and Right split
- A preparedness system that funds a known-promising candidate only once people start dying, or deliverable-tied money backing the one candidate that can prove itself in humans.
How left and right read it
CEPI committed up to $8.5 million on July 30 for Hilleman to make the first clinical-trial doses of a Bundibugyo vaccine — doses expected only by year's end, with human studies after. The outbreak was declared in mid-May and has killed 1,556 people, a 44.1% fatality rate. Congolese authorities say the peak has not arrived. Why does a candidate WHO calls most promising, on the same platform as the licensed Ervebo, reach manufacturing only after the dying starts?
Up to $8.5 million, tied to concrete deliverables — finalise the manufacturing process, produce the first clinical-trial doses, then human studies — is the kind of bounded, accountable commitment worth defending, especially built on the rVSV backbone behind the only licensed Ebola vaccine. With no approved vaccine or treatment for Bundibugyo and a 44.1% fatality rate, seriousness means candidates that enter human testing and show it, not prototypes reported immunogenic against surrogate viruses.
The receipts — 48 sources
Wire services (3)
Independent coverage (45)
The news, read by both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.